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Abstract
Xenografting primary human solid tumor tissue into immunodeficient mice is a widely used tool in studies of human cancer
biology; however, care must be taken to prove that the tumors obtained recapitulate parent tissue. We xenografted primary
human hepatocellular carcinoma (HCC) tumor fragments or bulk tumor cell suspensions into immunodeficient mice. We
unexpectedly observed that 11 of 21 xenografts generated from 16 independent patient samples resembled lymphoid
neoplasms rather than HCC. Immunohistochemistry and flow cytometry analyses revealed that the lymphoid neoplasms
were comprised of cells expressing human CD45 and CD19/20, consistent with human B lymphocytes. In situ hybridization
was strongly positive for Epstein-Barr virus (EBV) encoded RNA. Genomic analysis revealed unique monoclonal or
oligoclonal immunoglobulin heavy chain gene rearrangements in each B-cell neoplasm. These data demonstrate that the
lymphoid neoplasms were EBV-associated human B-cell lymphomas. Analogous to EBV-associated lymphoproliferative
disorders in immunocompromised humans, the human lymphomas in these HCC xenografts likely developed from
reactivation of latent EBV in intratumoral passenger B lymphocytes following their xenotransplantation into
immunodeficient recipient mice. Given the high prevalence of latent EBV infection in humans and the universal presence
of B lymphocytes in solid tumors, this potentially confounding process represents an important pitfall of human solid tumor
xenografting. This phenomenon can be recognized and avoided by routine phenotyping of primary tumors and xenografts
with human leukocyte markers, and provides a compelling biological rationale for exclusion of these cells from human solid
tumor xenotransplantation assays.
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Introduction
Xenotransplantation of human cancers into immunodeficient
mice is very useful for studying human tumor biology [1]. This
approach is widely used for research into mechanisms of tumor
growth and for preclinical evaluation of anti-cancer therapies
[2,3]. The most commonly utilized mouse strains, such as the non-
obese diabetic severe combined immunodeficiency (NOD/SCID)
and NOD/SCID/interleukin 2 receptor gamma chain null (NSG)
strains, are deficient in both innate and adaptive immunity and
thereby permit the survival of human tissue [4,5].
While it is possible to generate xenografts from purified
populations of cells from some human cancers [6–9], many
studies describe the implantation of tumor fragments or bulk
tumor cell suspensions in mice to maximize the chances of
establishing xenografts from limited clinical samples [10–13].
Reports describing xenografts from human hepatocellular carci-
noma (HCC), for example, reveal that only 10–20% of clinical
samples yielded viable xenografts when dissociated into cell
suspensions that were further fractionated for implantation in
mice [14,15].
Epstein-Barr virus (EBV) is a human-restricted herpes virus
which infects over 90% of the human population, persisting as a
latent infection for the lifetime of the host [16,17]. EBV
preferentially infects B lymphocytes and ‘‘transforms’’ them into
a proliferative state by altering cellular gene transcription,
constitutively activating key cell-signalling pathways, and prevent-
ing apoptosis [18]. In immunocompetent individuals, EBV is well
controlled by cellular and humoral immunity, and transformed B
cells are continually eliminated because they express foreign
antigens. Individuals who are immunocompromised, such as
patients with HIV/AIDS or those receiving immunosuppressive
drugs following transplantation, are at risk of developing B-cell
lymphomas from the uncontrolled proliferation of EBV-trans-
formed cells [17,19,20]. Similarly, spontaneous development of
EBV-associated human lymphomas has been described in
immunodeficient mice repopulated with normal human hemato-
poietic cells due to reactivation of latent EBV [21].
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HCC specimens, we implanted tumor fragments or bulk tumor
cell suspensions into immunodeficient mice. To validate our
model, we carefully examined xenografts to determine how
accurately they recapitulated parent tumors. Unexpectedly, we
observed that several xenografts did not resemble HCC, and
sought to characterize these tumors further in order to understand
potential pitfalls of our xenotransplantation assay. In this report,
we describe how our further characterization of these atypical
xenografts revealed them to be EBV-associated human B-cell
lymphomas and discuss the implications of this observation.
Results and Discussion
As summarized in Table 1, we obtained fresh HCC samples
from 16 consecutive patients who were undergoing surgical
resection of their tumors as primary therapy. None of the patients
had received any form of neoadjuvant therapy. The diagnosis of
HCC and degree of tumor differentiation in each resected
specimen was determined through standard diagnostic assessments
performed by clinical hepatopathologists at our institution
independent of this study. Of 21 xenografts generated from the
16 different HCC specimens, we identified only 10 xenografts that
resembled HCC on initial histopathological assessment (‘‘HCC-
like xenografts’’). The remaining 11 xenografts resembled
lymphoid neoplasms rather than HCC (‘‘non-HCC-like xeno-
grafts’’). In comparing the groups of patient samples that yielded
HCC-like xenografts as compared with those that yielded non-
HCC-like xenografts, there were no obvious differences between
groups in patient age (68611 years vs. 62610 years, p=0.27),
underlying liver disease, or degree of differentiation of primary
tumors. HCC-like and non-HCC-like xenografts arose in both
NOD/SCID and NSG mice, and the time intervals between HCC
implantation and harvesting of the first xenografts were similar
(180681 days vs. 144665 days, p=0.28).
As shown in Figure 1A, HCC-like xenografts shared many
histological features of HCC with parent tumors, including
hepatocyte-like cells with nuclear atypia and high nuclear-to-
cytoplasmic ratio, absence of portal tracts, and distorted trabeculae
with increased thickness of hepatocellular plates. As shown in
Figure 1B, non-HCC-like xenografts differed significantly from
parent HCC tumors and HCC-like xenografts. Non-HCC-like
xenografts had no architectural features of HCC, instead
consisting of monomorphic populations of small lymphoid
mononuclear cells with nuclear atypia and high mitotic index.
As shown in Figure 1C, analysis of xenografts by RT-PCR
revealed that HCC-like xenografts retained expression of many
liver cell markers, while these were diminished or absent in non-
HCC-like xenografts. We suspect that the persistent detection of
liver epithelial markers such as cytokeratins, AAT and TDO in
some non-HCC-like xenografts reflects the extreme sensitivity of
RT-PCR to detect the presence of some persisting HCC cells in
non-HCC-like xenografts despite near replacement of the
originally implanted HCC tissue by rapidly proliferating lymphoid
cells.
Due to the resemblance of non-HCC-like xenografts to
lymphoid neoplasms, we evaluated the expression of human and
murine leukocyte markers by immunohistochemistry. In contrast
to the typically sparse distribution of leukocytes observed in all of
the parent human HCC tissues to a similar extent mainly along
portal tracts when they were invaded by the tumor (Figure 2A),
non-HCC-like xenografts were densely infiltrated or replaced by
cells that could be characterized as human B lymphocytes by their
expression of human CD45 and CD20 (Figure 2B). Flow
cytometry confirmed that the human CD45
+ population consisted
predominantly of CD19
+ cells, consistent with human B lympho-
cytes (Figure 2C). Staining for the human T-cell antigen CD3 was
minimal, as was staining for the mouse lymphocyte antigen B220
and the mouse histocompatibility antigen H2k (data not shown).
We did not identify any correlation between leukocyte infiltration
in parent HCC tissues and the development of non-HCC-like
xenografts. In addition, prior to their HCC resection, none of the
source patients had a history of lymphoproliferative disease or an
immunodeficient state known to predispose to lymphoproliferative
disorders (eg. human immunodeficiency virus infection, pharma-
cological immunosuppression).
Cognizant of the importance of EBV in the pathogenesis of
lymphoproliferative disorders in immunocompromised humans
[18], we evaluated our xenografts for evidence of EBV infection by
in situ hybridization (ISH) for EBV-encoded RNA (EBER), and
found that this was strongly positive in the B lymphocytes
populating the non-HCC-like xenografts (Figure 2B). We were
unable to determine the presence or absence of latent EBV in
parent HCC specimens using EBER ISH and PCR for EBV
DNA, and this needs to be prospectively evaluated. Since EBV is
so effectively suppressed in immunocompetent humans, we suspect
that the tiny amount of EBER and EBV DNA that would be
present in a few B-cells in the source tumor, of which we had
extremely limited histological sections for retrospective analysis,
was below the detection threshold of our assays. Preoperative EBV
serology of source patients was not available since this is not
routinely tested.
To further characterize the non-HCC-like xenografts, we
evaluated the clonality of the human B lymphocyte proliferations
by assaying immunoglobulin heavy chain (IgH) gene rearrange-
ments. As shown in Figure 3, B-cell proliferations arose from a
single clone in 10 of 11 non-HCC-like xenografts, and from two
clones in the remaining case. In two instances, independent
xenografts obtained from separate fragments of a single parent
HCC developed into lymphoid tumors that demonstrated different
IgH rearrangements. This suggests that the malignant transfor-
mation and clonal expansion responsible for the EBV-associated
lymphomas observed in this study occurred subsequent to the
xenotransplantation of human tissue into immunodeficient mice,
and that lymphomas were not already present in source tissues.
To exclude contamination by a lymphocyte cell line or cross-
contamination between xenografts as a source of the lymphomas,
we performed short tandem repeat (STR) analysis on genomic
DNA from each xenograft and confirmed that xenografts from
different patients were genetically distinct (Table 2).
Collectively, these findings demonstrate that non-HCC-like
xenografts were comprised of EBV-associated human B-cell
lymphomas that had developed spontaneously from xenografted
human HCC tissues. Analogous to EBV-associated lymphoprolif-
erative disorders in immunocompromised humans, this likely
occurred through reactivation of latent EBV and malignant
transformation of intratumoral passenger B lymphocytes made
possible by the immunodeficiency of the recipient mice. In future
work, we plan to apply cell sorting techniques to exclude CD45
+
cells from human HCC samples prior to xenotransplantation in
order to prevent this process.
The phenomenon of EBV-associated lymphomagenesis has not
been reported in the context of human solid tumor xenografts.
Considering the high prevalence of latent EBV in humans [16]
and the presence of B lymphocytes in solid tumors from all human
tissues [22], it is likely that most solid tumors would be vulnerable
to this process. It is unlikely that this phenomenon is unique to
HCC, as EBV has not been implicated in the pathogenesis of
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very rare [24], and there is no clearly established causative link
between chronic liver disease and the incidence of lymphoprolif-
erative disease. We thus believe that our observations are of
importance to all investigators utilizing human solid tumor
xenotransplantation assays. As we have shown, lymphomas can
arise within the first xenografts obtained, and do not require serial
tumor passaging. Unrecognized, this process may confound
experimental data such as measures of tumor growth and markers
of tumor cell populations. Lymphomas may also competitively
eliminate the tumor tissue of interest, resulting in loss of valuable
samples.
This process can best be recognized through phenotyping of
xenografted tissues using leukocyte markers. Histopathological
assessment is not sufficient, as lymphomas may be misinterpreted
as poorly differentiated epithelial tumors. Initial growth kinetics of
lymphomas in our model was similar to HCC-like xenografts,
indicating that this process cannot be detected by gross
observations alone. Because lymphomas may arise from one or
two B-cell clones, immunomagnetic depletion of CD45
+ cells may
not be sufficient to prevent this process since all CD45
+ cells are
not removed [25]. Flow cytometry-based single-cell sorting is the
most stringent technique to identify and eliminate human
leukocytes from solid tumor xenotransplantation assays. Most
rigorous analyses of human solid cancer xenografts incorporate
routine quantification, exclusion or depletion of contaminating
CD45
+ cells from assays targeting biological and functional
properties of specific subpopulations of tumor cells [26]; our
observations provide a compelling biological rationale to support
this practice and extend it to include all observations involving
solid tumor xenografts.
It is important to note that the generalizability of our
observations should be interpreted with caution in the context of
a relatively small sample size of patients, HCC specimens, and
xenografts. The clinical characteristics of the source patients are
observational only and were retrospectively analyzed, making this
study vulnerable to potentially confounding patient factors or
differences that it is underpowered to detect. Similarly, although
our data does not demonstrate any obvious relationships between
the xenografting methods used (eg. tumor fragment vs. cell
suspension, NSG vs. NOD/SCID mouse strain) and the develop-
ment of EBV-associated lymphomas, the study is underpowered to
detect the relative influence of these variables on the results.
In summary, we have shown that human solid tumor xenografts
in immunodeficient mice are vulnerable to lymphomagenesis
associated with EBV. This potentially confounding process can be
recognized through immunophenotyping of xenografts using
leukocyte markers and should be preventable by excluding
leukocytes from source tissues. This phenomenon should be
recognized as an important pitfall of human solid tumor
xenotransplantation assays.
Table 1. Patient demographics, parent HCC grade, and xenograft characteristics.
Xenograft
Histology
Sample
ID
Patient
Age (yr)
Patient
Sex
Liver
Disease
HCC
Grade
a
Mouse
Strain
Proportion of
Mice with
Xenografts
Days to
Xenograft
b
From HCC
Fragment
From HCC
Cell
Suspension
HCC-like 51853 65 Male Hepatitis C Poor NSG – 2/4 215, 250
c
55368 62 Male NASH
d Moderate NOD/SCID 1/4 – 64
58063 81 Female Hepatitis B Poor NOD/SCID 1/3 – 301
59394 66 Male Hepatitis C Moderate NOD/SCID 2/2 – 133, 209
c
59410 50 Female Hepatitis B Moderate NOD/SCID 0/2 1/1 120
59826 69 Female Alcohol Moderate NSG 2/2 0/2 85, 148
c
60333 83 Female Hepatitis B Moderate NSG 0/2 1/1 272
Non-HCC-like
(lymphoid)
54069 72 Male Cryptogenic Moderate NSG 1/6 – 140
54307 60 Male Hepatitis C Moderate NSG 2/2 – 100, 140
c
55727 83 Female Hepatitis B Moderate NOD/SCID 2/5 – 116, 193
c
57602 61 Male Hepatitis C Moderate NSG 1/3 0/2 85
58424 60 Male Hepatitis C Poor NOD/SCID 1/3 – 125
59676 50 Male Cryptogenic Moderate NSG 1/2 0/2 171
59957 59 Male NASH Moderate NSG 0/3 1/1 314
60665 61 Male Hepatitis B Moderate NSG 0/3 1/2 106
62033 51 Male Hepatitis B
and NASH
Poor NSG 1/4 – 92
aDegree of tumor differentiation documented in clinical pathology report.
bNumber of days between implantation of tumor sample and harvesting of a 1.5 cm3 xenograft.
cBoth xenografts demonstrated similar histology.
dNon-alcoholic steatohepatitis.
doi:10.1371/journal.pone.0039294.t001
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PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e39294Figure 1. Xenografts arising from human HCC specimens. (A) Representative H&E sections (6200) of parent HCC tumors from three different
patients (top panels) and the corresponding xenografts (bottom panels), which share typical histopathological features of HCC. (B) Representative
H&E sections (6200) of parent HCC tumors from three different patients (top panels) that show typical features of HCC in contrast to the
corresponding xenografts (bottom panels) which resemble lymphoid neoplasms. (C) RT-PCR demonstrating that xenografts which retain
histopathological features of HCC (‘‘HCC-like xenografts’’) express typical liver cell markers, while many of these markers are absent from xenografts
that do not resemble HCC histopathologically (‘‘non-HCC-like xenografts’’) (composite image; ALB – albumin, AFP – alphafetoprotein, AAT – alpha-1-
antitrypsin, TAT – tyrosine aminotransferase, TDO – tryptophan-2,3-dioxygenase, G6P – glucose-6-phosphate dehydrogenase, CK8/18/19 –
cytokeratin 8/18/19, GAPDH – glyceraldehyde phosphate dehdrogenase).
doi:10.1371/journal.pone.0039294.g001
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PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e39294Figure 2. Expression of leukocyte markers and EBER in non-HCC-like xenografts. (A) Representative section (6200) from a parent HCC
sample that gave rise to a non-HCC-like xenograft, demonstrating a typical distribution of CD45
+ leukocytes along a portal tract invaded by the
tumor, only a small fraction of which are CD20
+ B lymphocytes; EBER ISH is negative. (B) Representative sections (6400) from three non-HCC-like
xenografts demonstrating that a very high proportion of cells stain positively for human CD45 and human CD20 (brown), consistent with human B
lymphocytes; EBER ISH is very strongly positive in the cells in these xenografts (dark blue). (C) Representative multiparameter flow cytometry analysis
of freshly isolated cells from a non-HCC-like xenograft demonstrating that a large proportion of tumor cells are human CD45
+ leukocytes (left plot),
and that the majority of the gated CD45
+ population also expresses human CD19
+ (right plot), consistent with B lymphocytes.
doi:10.1371/journal.pone.0039294.g002
EBV-Associated Lymphomas in Human Tumor Xenografts
PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e39294Materials and Methods
Ethics statement
Ethical approvals were obtained from the University Health
Network Research Ethics Board (Protocol #08-0697-TE) and
Animal Care Committee (Animal Use Protocol #1595). Human
tissues were obtained with written consent from source patients.
Patient samples
Human HCC samples and demographic data were obtained
from patients undergoing surgery and anonymized with 5-digit
numbers. Tumor samples were obtained only from patients for
whom surgical resection was the primary form of HCC treatment,
and who had not received any form of systemic or locoregional
neoadjuvant therapy (eg. systemic chemotherapy, intrahepatic
chemotherapy, radiofrequency tumor ablation, external beam
radiation therapy). Fresh surgical resection specimens were
transferred from the operating room to the surgical pathology
suite within 15 minutes of removal from the patient and promptly
sectioned by the attending clinical pathologist. Samples for
xenografting were taken from the peripheral zone of the tumor
in all cases, and appeared grossly viable and non-necrotic. Samples
were placed in serum-free Dulbecco’s Modified Eagle Medium
(DMEM, Life Technologies) at 4 degrees Celsius and transferred
to the research laboratory for immediate processing and implan-
tation into recipient mice. HCC diagnoses were subsequently
verified in all cases using clinical pathology reports issued
independent of this study.
Xenografts
Bulk tumor cell suspensions were prepared by digestion with
Type IV Collagenase (Sigma) for 30–60 minutes at 37uC, passage
through a 70 mm cell strainer (BD Biosciences) and lysis of red
blood cells using RBC lysis buffer (eBioscience). Following trypan
blue analysis, 106 viable cells were resuspended in 50 mlo f
Matrigel (BD Biosciences) and injected subcutaneously with a 25
gauge needle into the flanks of anesthetized NOD/SCID or NSG
mice. No attempt was made to separate HCC cells from other cell
populations within tumor samples. Alternatively, 3 mm3 tumor
fragments in Matrigel were implanted subcutaneously on the
flanks through a 5 mm skin incision. Priority was given to
implantation of tumor fragments; bulk cell suspensions were
injected if sufficient tumor tissue was available and if the fraction of
viable cells in the tumor cell suspension exceeded 70%.
RT-PCR
RNA was isolated using TRIZOL Reagent (Life Technologies)
and reverse-transcribed using SuperScript First-Strand Synthesis
System (Invitrogen). PCR was performed with Taq DNA
Polymerase (New England Biolabs) using conventional thermo-
cycling protocols. Amplified products were visualized with
ethidium bromide agarose gel electrophoresis. Primer sets were
synthesized based on publicly available human nucleotide
sequences (see Table S1).
Histopathology
Formalin-fixed, paraffin-embedded tissues were utilized. For
immunohistochemistry, de-waxed sections were blocked with 3%
hydrogen peroxide, avidin/biotin blocking kit (Vector Labs), and
10% normal serum from the secondary Ab species, then incubated
at room temperature with primary Ab for 1 hour as follows: mouse
anti-human CD45 (1:80, Dako), mouse anti-human CD20 (1:100,
Dako), rabbit anti-human CD3 (1:300, Dako), or rat anti-mouse
B220 (1:1000, BD Biosciences). This was followed by biotin
labeled secondary Ab (Vector Labs) for 30 minutes and HRP-
conjugated ultrastreptavidin labeling reagent (ID Labs) for
30 minutes. Color was developed with DAB solution (Dako).
Sections were counterstained with Mayer’s hematoxylin, dehy-
drated and mounted in Permount (Fisher). In situ hybridization for
EBER was performed on a Ventana Medical Systems automated
slide stainer employing EBER probes and the Ventana ISH
iVIEW Blue Detection Kit according to manufacturer instruc-
tions.
Flow cytometry
Cells were blocked in PBS containing 0.5% BSA and human
FcR Blocking Reagent (Miltenyi Biotec), then incubated with anti-
mouse H2-K [d] FITC (SF1-1.1, BD Biosciences), anti-human
CD45 PE-Cy7 (HI30, BD Biosciences), anti-human CD3 Alexa
Fluor 647 (UCHT1, BioLegend) and anti-human CD19 PE
(HIB19, BioLegend), or with FITC Mouse IgG2a, k (G155-178,
BD Biosciences), PE-Cy7 Mouse IgG1, k (MOPC-21, BD
Biosciences), Alexa Fluor 647 Mouse IgG1, k (MOPC-21, BD
Biosciences) and PE Mouse IgG1, k (MOPC-21, BD Biosciences)
isotype controls. After washing, cells were incubated with Live/
Dead Fixable Violet Dead Cell Stain Kit (Invitrogen) and analyzed
using LSR II Flow Cytometer (BD Biosciences) with FlowJo
V8.8.6.
IgH gene rearrangement assay
DNA was isolated using GenElute Mammalian Genomic DNA
Miniprep Kit (Sigma). Clonality was evaluated by PCR for VDJ
rearrangement of the IgH gene using primers directed at
framework three of the V segments (IgHV: ACACGGCC(A/C/
G)TGTATTACTGT) and J segments (IgHJ: TGAGGA-
GACGGTGACC), flanking the hypervariable gene region. PCR
was performed with Taq DNA Polymerase (New England Biolabs)
and conventional thermocycling protocols. Amplified fragments
Figure 3. Immunoglobulin heavy chain gene rearrangements in non-HCC-like xenografts. PCR amplification of the variable region of the
human IgH gene demonstrating unique dominant rearrangements in all of the non-HCC-like xenografts, confirming clonal B-cell proliferation.
Dominant rearrangements were not amplified in HCC-like xenografts. Successful amplification of the b-globin gene confirms integrity of the genomic
DNA analyzed.
doi:10.1371/journal.pone.0039294.g003
EBV-Associated Lymphomas in Human Tumor Xenografts
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Clonality was determined by the number of dominant bands, and
bands of unique size were interpreted as products of distinct B-cell
clones.
STR analysis
Genotyping was performed using the AmpFlSTR Identifiler
PCR Amplification Kit (Life Technologies) that employs a
multiplex assay which amplifies 15 tetranucleotide repeat loci
and the Amelogenin gender determining marker. Samples were
run on an ABI 3100 Genetic Analyzer and analyzed in
GeneMapper v3.7.
Statistical analysis
Where applicable, unpaired t-tests were used to compare means
between two groups and statistical significance was expressed with
two-tailed P values.
Supporting Information
Table S1 PCR primer sets.
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